Bruton's tyrosine kinase - Open Access .click

Results 221 to 230 of about 5,286 (232)

Some of the next articles are maybe not open access.

Clinical Potential of Targeting Bruton's Tyrosine Kinase

International Reviews of Immunology, 2008
Targeting Bruton's tyrosine kinase (BTK) with a small-molecule inhibitor may be useful in treatment of BTK-expressing malignancies because of the antiapoptotic function of BTK in cancer cells. Furthermore, BTK inhibitors also exhibit antithrombotic properties, which may be desirable in the context of the increased risk of thromboembolic complications ...
openaire +2 more sources

Bruton's tyrosine kinase as a drug discovery target

Drug News & Perspectives, 2008
Bruton's tyrosine kinase (Btk) is an important mediator in multiple signal transduction pathways. Fifteen years of research have revealed a complex role for Btk in hematopoietic cells. These studies suggest that Btk may be a promising target for therapeutic intervention for several complicated diseases.
openaire +2 more sources

X-Linked Agammaglobulinemia and Bruton’s Tyrosine Kinase

1994
The genetic defect associated with human X-linked agammaglobulinemia (XLA) and murine X-linked immunodeficiency (XID) was recently identified as the deficiency of function of a new cytoplasmic tyrosine kinase called Bruton’s tyrosine kinase (Btk)1,2,3,4. The phenotypes associated with these immunodeficiencies indicate that Btk plays a crucial role in B
S, Tsukada, O N, Witte
openaire +2 more sources

Next-Generation Bruton Tyrosine Kinase Inhibitors

Journal of Clinical Oncology, 2020
Deborah M, Stephens, John C, Byrd
openaire +2 more sources

The many faces of Bruton's tyrosine kinase

Nature Biotechnology, 2012
openaire +2 more sources

Bruton's tyrosine kinase in systemic lupus erythematosus